Company profile
OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also
- CEO
- —
- Headquarters
- Bellevue, WA, United States
- Employees
- 22
- IPO date
- Mar 17, 2023
- Sector
- Healthcare
- Industry
- Biotechnology